#EventFreeSurvival
LightNews LightNews
haravanews.bsky.social
AstraZeneca’s phase 3 VOLGA trial found lower hazards of an event and death with durvalumab plus enfortumab vedotin around surgery for patients unable or unwilling to take cisplatin.

#BladderCancer #VOLGATrial #Durvalumab #EnfortumabVedotin #Cisplatin #EventFreeSurvival
[AI]
Can This Regimen Change Bladder Cancer Care?
VOLGA reported improved event-free and overall survival with durvalumab and enfortumab vedotin, but FDA review and comparisons remain.
harava.news
October 25, 2026 at 12:13 PM
oncodaily.bsky.social
Pfizer’s Sasanlimab with BCG Improved Event-Free Survival in High-Risk Bladder Cancer

oncodaily.com/insight/sasa...

#BladderCancer #Cancer #EventFreeSurvival #EFS #OncoDaily #Oncology #Pfizer #Sasanlimab
Pfizer’s Sasanlimab with BCG Improved Event-Free Survival in High-Risk Bladder Cancer - OncoDaily
Pfizer’s Sasanlimab with BCG Improved Event-Free Survival in High-Risk Bladder Cancer / bladder cancer, cancer, event-free survival (EFS), Neal Shore,
oncodaily.com
January 12, 2025 at 4:43 PM